Our singular mission is to develop and deliver intelligent therapeutics to address the neglected or under-served medical needs of patients with respiratory rare diseases. Deploy drugs, drug-drug, drug-device, and health informatics to minimize risks and drive a rapid and cost-effective development aimed at providing therapies with a meaningful impact on the everyday lives of patients and limit disease progression and irreversible lung damage....
Our singular mission is to develop and deliver intelligent therapeutics to address the neglected or under-served medical needs of patients with respiratory rare diseases. Deploy drugs, drug-drug, drug-device, and health informatics to minimize risks and drive a rapid and cost-effective development aimed at providing therapies with a meaningful impact on the everyday lives of patients and limit disease progression and irreversible lung damage.
More information

Investors

Chris Robinson
Admin
Chris Robinson
Alan Taggart
Admin
Alan Taggart

Employees

Safia K. Rizvi
Admin
Safia K. Rizvi CEO I am a fully integrated drug-dealer who used to discover drugs and have been commercializing them for several years ( ethical Pharmaceutical)
Larry Lands
Admin
Larry Lands

Recommendations

I am excited to congratulate CILA on its successful launch and vision to improve lives with its therapeutic respiratory products. I am especially excited to support its CEO, Dr Safia Rizvi, who I believe is an extremely dynamic and brilliant executive leader. I had the pleasure of knowing Safia for over a decade as an accomplished executive leader in the bio/pharmaceutical industry. So I was delighted to sit down with her this past year to understand her vision at CILA, and provide early investment to help her get started. I am excited to hear the progress that she and her new team at CILA have made and certainly provide my ongoing support for her application for funding. I hope that your support helps CILA bring its products to market as quickly as possible in order to potentially benefit the lives of so many.